World AMR Congress

INNOVATE.
COLLABORATE.
COMMERCIALIZE.

Bringing together pharma, biotech, hospitals, Government and their partners to discuss the world’s most important health issue.  

 

 

 

 

FACING A GLOBAL HEALTH CRISIS

 

The World AntiMicrobial Resistance Congress USA gathers C-level decision makers from government, funding agencies, pharma, academia, hospitals, labs, and payers to discuss the urgent need for new antibiotics. President Obama has outlined his 5-year action plan to fight AMR and is seeking to double the AMR funding to $1.2B, but the bigger challenge is how to deliver these actions.

This 2-day conference presents solutions through key notes, case study presentations, expert opinion and roundtable discussions, and invites key influencers such as BARDA, NIH, FDA, grant agencies, pharma and academia, in the AMR discussion. This is the 2-day exhibition and conference you cannot afford to miss.

Dx and target discovery

Infection prevention and non-traditional antibiotics

Clinical development

Pitch and partner

Sustainable business approaches to AMR antibiotic development

GAIN Act, QIDP and market authorization

Commercialization and reibursement

 

 

" The evolution of antibiotic resistance is now occurring at an alarming rate and is outpacing the development of new countermeasures capable of thwarting infections in humans. "

President Barack Obama

Meet the experts

 

The World Anti-Microbial Resistance Congress 2016 is bringing togehter all of the greatest minds in the antimicrobial field together to tackle this very issue. It’s time to stop talking about the problem and start discussing solutions, which is why we brought in Pharma, academia and the government.

 

  • Rosemarie Aurigemma at World Anti-Microbial Congress US 2016
    Rosemarie Aurigemma
    Chief Biodefense Drug Development Section
    NIAID, NIH
    Stefano Bertuzzi at World Anti-Microbial Congress US 2016
    Stefano Bertuzzi
    Executive Director/CEO
    American Society for Microbiology
  • Thomas Chen at World Anti-Microbial Congress US 2016
    Thomas Chen
    Global Anti Infective Franchise Head
    Basilea Pharmaceutica Ltd
    James Del Rosso at World Anti-Microbial Congress US 2016
    James Del Rosso
    DO, FAOCD, FAAD, Adjunct Clinical Professor, (Dermatology)
    Touro University Nevada
  • Michael Draper at World Anti-Microbial Congress US 2016
    Michael Draper
    Senior Director, External Science and Partnering
    Sanofi
    Michael Dudley at World Anti-Microbial Congress US 2016
    Michael Dudley
    Senior Vice President of Research and Development and Chief Scientific Officer
    The Medicines Company
  • Erin Duffy at World Anti-Microbial Congress US 2016
    Erin Duffy
    Chief Scientific Officer
    Melinta Therapeutics Inc
    Jens Eckstein at World Anti-Microbial Congress US 2016
    Jens Eckstein
    President
    S.R. One
  • Barry Eisenstein at World Anti-Microbial Congress US 2016
    Barry Eisenstein
    Distinguished Physician, Antimicrobials
    Merck & Co.
    Robert Eisinger at World Anti-Microbial Congress US 2016
    Robert Eisinger
    Senior Health Science Policy Advisor, Division of Program Coordination, Planning, and Strategic Initiatives,
    NIH
  • Fabrizio Ensoli at World Anti-Microbial Congress US 2016
    Fabrizio Ensoli
    Head,Pathology and Microbiology
    Sapienza University of Rome
    Marcos Espinal at World Anti-Microbial Congress US 2016
    Marcos Espinal
    Director, Department of Communicable Diseases and Health Analysis
    PAHO/WHO
  • Scott Evans at World Anti-Microbial Congress US 2016
    Scott Evans
    Director of the Statistical and Data Management Center (SDMC) for the Antibacterial Resistance Leadership Group (ARLG)
    Harvard University
    Tamar Ghosh at World Anti-Microbial Congress US 2016
    Tamar Ghosh
    Lead, Longitude Prize
    Nesta
  • Steven Gilman at World Anti-Microbial Congress US 2016
    Steven Gilman
    Chairman & CEO
    Contrafect Corporation
    Judy Hackett at World Anti-Microbial Congress US 2016
    Judy Hackett
    Project Coordinator, Drive-AB, Global Payer Evidence Director
    AstraZeneca
  • Chris Houchens at World Anti-Microbial Congress US 2016
    Chris Houchens
    PhD, Branch Chief (Acting), Antibacterials Program
    BARDA
    Hasan Jafri at World Anti-Microbial Congress US 2016
    Hasan Jafri
    Senior Director, Clinical Research and Development Infectious Diseases and Vaccines MedImmune, AstraZeneca,Coordinator, COMBACTE
    Innovative Medicines Initiative
  • François Jehl at World Anti-Microbial Congress US 2016
    François Jehl
    Bacteriology Lab manager, Hospital Strasbourg, France, Coordinator, Antimicrobial Committee
    French Society for Microbiology
    Anders Karlén at World Anti-Microbial Congress US 2016
    Anders Karlén
    Managing Entity, ENABLE, Professor in Computer-aided Drug Design
    Uppsala University
  • Barbara Kerstiens at World Anti-Microbial Congress US 2016
    Barbara Kerstiens
    Deputy Head of Unit, Fighting Infectious Diseases and Advancing Public Health Research and Innovation Directorate-General
    European Commission
    Dr Jane Knisely at World Anti-Microbial Congress US 2016
    Dr Jane Knisely
    Program Officer, Bacteriology and Mycology Branch, NIAID
    NIH - NIAID
  • Joe Larsen at World Anti-Microbial Congress US 2016
    Joe Larsen
    Acting Deputy Director
    BARDA
    Frédéric Laurent at World Anti-Microbial Congress US 2016
    Frédéric Laurent
    Professor of Microbiology, National Reference Center on Staphylococcus
    University Hospital, Lyon
  • Ankit Mahadevia at World Anti-Microbial Congress US 2016
    Ankit Mahadevia
    Chief Executive Officer
    Spero Therapeutics
    David Mantus at World Anti-Microbial Congress US 2016
    David Mantus
    Chief Development Officer
    Arsanis
  • Anthony McDonnell at World Anti-Microbial Congress US 2016
    Anthony McDonnell
    Head of Economic Research
    Review on Antimicrobial Resistance
    Sumathi Nambiar at World Anti-Microbial Congress US 2016
    Sumathi Nambiar
    Director, Division of Aniti-Infective Products
    FDA
  • Professor Kevin Outterson at World Anti-Microbial Congress US 2016
    Professor Kevin Outterson
    Professor of Health Law, Bioethics and Human Rights
    Boston University School of Law
    Jean Patel at World Anti-Microbial Congress US 2016
    Jean Patel
    Deputy Director, Office of Antimicrobial Resistance
    Center for Disease Control & Prevention
  • Robin Patel at World Anti-Microbial Congress US 2016
    Robin Patel
    Professor of Microbiology and Medicine
    Mayo Clinic
    Edmund Pezalla at World Anti-Microbial Congress US 2016
    Edmund Pezalla
    VP
    Aetna Pharmacy Management
  • Aleks Radovic-Moreno at World Anti-Microbial Congress US 2016
    Aleks Radovic-Moreno
    Senior Associate
    PureTech Health
    Ribhi Shawar at World Anti-Microbial Congress US 2016
    Ribhi Shawar
    Branch Chief, Division of Microbiology
    CDRH OIR FDA
  • Carolyn Shore at World Anti-Microbial Congress US 2016
    Carolyn Shore
    Officer of Antibiotic Resistance Project
    The Pew Charitable Trusts
    Mr Larry Tsai at World Anti-Microbial Congress US 2016
    Mr Larry Tsai
    VP, Clinical Development
    Tetraphase Pharmaceuticals
  • Lucas Wiarda at World Anti-Microbial Congress US 2016
    Lucas Wiarda
    Global Marketing Director & Head of Sustainable Antibiotics Program
    DSM Sinochem Pharmaceuticals
    Chen Yu at World Anti-Microbial Congress US 2016
    Chen Yu
    Managing Partner
    Vivo Capital

 

" [AMR] is an increasingly serious threat to global public health that requires action across all government sectors and society. "

World Health Organization

Why Sponsor?

Forge new partnerships

Generate new leads

World AntiMicrobial Resistance Congress USA

Build brand presence

Promote new services

SPONSOR NOW
 

Our Sponsors & Exhibitors

 

  • Platinum Sponsor

    Biofilm Control at World Anti-Microbial Congress US 2016
 

JOIN THEM

 

Take a look at the sponsorship brochure

It helps explain how you can get involved with World AntiMicrobial Resistance Congress USA 2016.  


GET YOUR COPY HERE


 
 

" We’re in the post-antibiotic era. There are patients for whom we have no therapy, and we are literally in a position of having a patient in a bed who has an infection, something that five years ago even we could have treated, but now we can’t. "

Dr. Arjun Srinivasan, Centers for Disease Control and Prevention (CDC)

Register Now

THIS CONFERENCE WILL SELL OUT!
Early registration and partner discounts available.
Click below for the full list of ticket options...

 

REGISTER NOW

 

Error processing SSI file